Skip to content

Find our latest news, stories and insights

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Catch up on the latest press releases and download media assets here

  1. Home/
  2. News/
  3. Caring & giving/
  4. Ensuring babies have the first breath of life
Our-Giving-Ensuring-Babies-Have-the-First-Breath-of-Life
When Sun Yan’s daughter Wu Yuxuan was born, she could not breathe on her own until nurses performed life-giving resuscitation.

Ensuring babies have the first breath of life

When Sun Yan’s daughter Wu Yuxuan was born, she could not breathe on her own until nurses performed life-giving resuscitation.

The Helping Babies Breathe (HBB) initiative trains health care workers in low-resource settings to intervene when newborns have birth asphyxia, the inability to breathe at birth. HBB is committed to increase the availability of skilled birth attendants at every birth. Nurses and midwives with HBB training have the skills to resuscitate over 90% of babies with birth asphyxia.

In 2011, Johnson & Johnson made a $2 million 5-year investment to implement HBB in Malawi and Uganda in partnership with Save the Children. The partnership has trained more than 1000 skilled birth attendants, mostly midwives.

HBB is an extension of over a decade of work with the Neonatal Resuscitation Program to address birth asphyxia, including a joint effort in China by Johnson & Johnson, the Chinese Ministry of Health and the American Academy of Pediatrics that has saved more than 190,000 babies. Since the program launched in 2004, newborn death caused by birth asphyxia has declined in China by more than 50% percent.

To date, our programs address birth asphyxia in more than 12 countries including China, India, Indonesia, Vietnam, Nepal, Pakistan, Uganda, Malawi, Kenya, Ethiopia, Ghana and South Africa.

More from Johnson & Johnson

Moving toward a more personalized approach to treating depression

The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.

“Our goal is a solution for every bladder cancer patient”

Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world.

Is this the end of one-size-fits-all treatments for depression?

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.